Brilliant Violet 605™ anti-mouse CD19 Antibody

Pricing & Availability
Clone
6D5 (See other available formats)
Regulatory Status
RUO
Other Names
B4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
6D5_BV605_051812
C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
  • 6D5_BV605_051812
    C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
115539 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
115540 50 µg 229€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CD19-expressing K562 human erythroleukemia cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence7.

Application References
  1. Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
  2. Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
  3. Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
  4. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
  5. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  6. Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
  7. Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
  8. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  9. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  10. Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
  11. Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed
  12. Olive V, et al. 2013. Elife. 2:822. PubMed
  13. Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations
  1. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  2. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  3. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  4. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  5. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  6. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  7. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
  8. Kim E, et al. 2022. Immunity. 55:145. PubMed
  9. Paik D, et al. 2022. Nature. 603:907. PubMed
  10. Xiong E, et al. 2023. Front Immunol. 13:1083119. PubMed
  11. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
  12. Arruda DC, et al. 2022. J Control Release. 350:228. PubMed
  13. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
  14. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  15. Gawish R, et al. 2022. Elife. 11:. PubMed
  16. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  17. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  18. Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed
  19. Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
  20. Benhamou D, et al. 2018. Front Immunol. 2.260416667. PubMed
  21. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  22. Maisonneuve C, et al. 2021. Cell Reports. 34(4):108677. PubMed
  23. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
  24. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
  25. Zhang R, et al. 2021. MAbs. 13:1904546. PubMed
  26. Li J, et al. 2018. Immunity. 49:178. PubMed
  27. Hutter K, et al. 2020. FEBS J. . PubMed
  28. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  29. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
  30. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  31. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
  32. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  33. Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed
  34. White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed
  35. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  36. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
  37. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  38. Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed
  39. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  40. Kitajima Y, et al. 2022. Cells. 11:. PubMed
  41. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  42. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  43. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  44. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  45. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  46. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  47. Subramaniam N, et al. 2021. Blood Adv. 5:1259. PubMed
  48. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  49. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  50. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  51. Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed
  52. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
  53. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  54. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  55. Bramwell K, et al. 2015. J Immunol. 195: 1647 - 1656. PubMed
  56. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  57. Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
  58. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  59. Nascimento DC, et al. 2021. Immunity. :. PubMed
  60. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_2563067 (BioLegend Cat. No. 115539)
AB_2563067 (BioLegend Cat. No. 115540)

Antigen Details

Structure
Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution

Pro-B cells to mature B cells (during development), follicular dendritic cells

Function
Modulates B cell activation and differentiation
Ligand/Receptor
CD21, CD81, Leu-13
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.

Gene ID
12478 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

Other Formats

View All CD19 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD19 6D5 FC
Biotin anti-mouse CD19 6D5 FC
FITC anti-mouse CD19 6D5 FC
PE anti-mouse CD19 6D5 FC
PE/Cyanine5 anti-mouse CD19 6D5 FC
Purified anti-mouse CD19 6D5 FC,CyTOF®,IHC-F
PE/Cyanine7 anti-mouse CD19 6D5 FC
Alexa Fluor® 488 anti-mouse CD19 6D5 FC
Alexa Fluor® 647 anti-mouse CD19 6D5 FC,IHC-F
Pacific Blue™ anti-mouse CD19 6D5 FC
Alexa Fluor® 700 anti-mouse CD19 6D5 FC
APC/Cyanine7 anti-mouse CD19 6D5 FC
PerCP anti-mouse CD19 6D5 FC
PerCP/Cyanine5.5 anti-mouse CD19 6D5 FC
Alexa Fluor® 594 anti-mouse CD19 6D5 IHC-F,FC
Brilliant Violet 421™ anti-mouse CD19 6D5 FC,IHC-F
Brilliant Violet 570™ anti-mouse CD19 6D5 FC
Brilliant Violet 605™ anti-mouse CD19 6D5 FC
Brilliant Violet 650™ anti-mouse CD19 6D5 FC
Brilliant Violet 785™ anti-mouse CD19 6D5 FC
Brilliant Violet 510™ anti-mouse CD19 6D5 FC
Purified anti-mouse CD19 (Maxpar® Ready) 6D5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD19 6D5 FC
Brilliant Violet 711™ anti-mouse CD19 6D5 FC
APC/Fire™ 750 anti-mouse CD19 6D5 FC
TotalSeq™-A0093 anti-mouse CD19 6D5 PG
Brilliant Violet 750™ anti-mouse CD19 6D5 FC
TotalSeq™-B0093 anti-mouse CD19 6D5 PG
Spark Blue™ 550 anti-mouse CD19 6D5 FC
Spark NIR™ 685 anti-mouse CD19 6D5 FC
TotalSeq™-C0093 anti-mouse CD19 6D5 PG
Ultra-LEAF™ Purified anti-mouse CD19 6D5 FC,CyTOF®,IHC-F
PE/Fire™ 640 anti-mouse CD19 Antibody 6D5 FC
Spark YG™ 581 anti-mouse CD19 6D5 FC
APC/Fire™ 810 anti-mouse CD19 6D5 FC
Spark YG™ 570 anti-mouse CD19 6D5 IHC-F
Spark Blue™ 574 anti-mouse CD19 Antibody 6D5 FC
Spark Blue™ 515 anti-mouse CD19 6D5 FC
Spark UV™ 387 anti-mouse CD19 6D5 FC
Spark Red™ 718 anti-mouse CD19 (Flexi-Fluor™) 6D5 FC
Go To Top Version: 2    Revision Date: 05/24/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account